Skip to main content
Premium Trial:

Request an Annual Quote

BioTheranostics, DeNovo Partner for CTC Proof of Concept Studies

NEW YORK (GenomeWeb) – BioTheranostics today announced an agreement with DeNovo Sciences, a circulating tumor cell-based liquid biopsy company, to investigate the feasibility of using BioTheranostics’ proprietary biomarkers for blood-based cancer diagnostics.

According to BioTheranostics, the partners plan to perform proof-of-concept studies using DeNovo's Jetta CTC enrichment and single-cell analysis platform to enable the blood-based detection of undisclosed markers in BioTheranostics portfolio.

If successful, these initial studies could lead to the development of CTC-based liquid biopsy assays.

DeNovo Sciences develops automated systems for rare CTC enrichment and single-cell analysis, namely the label-free Jetta 400 system, which it says performs all the required processing steps to isolate and execute downstream single-cell analysis including immunochemistry, DNA FISH, and mRNA FISH.

“DeNovo Sciences has developed a differentiated platform that will allow us to recover CTCs for molecular characterization utilizing BioTheranostics’ high-resolution cancer biomarkers," Catherine Schnabel, BioTheranostics' chief scientific officer, said in a statement.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more